STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
The Supreme Court has rejected a challenge from several major drug manufacturers against the Medicare drug price negotiation program. This decision follows a series of unsuccessful lawsuits by companies such as AstraZeneca and Novartis. The court's refusal to hear the case aligns with previous lower court rulings, indicating a consensus on the matter.
- ▪The Supreme Court declined to take up lawsuits against the Medicare drug price negotiation program.
- ▪Drugmakers AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk were involved in the legal challenge.
- ▪The rejection of the case was expected as the drugmakers had lost their appeals in lower courts.
Opening excerpt (first ~120 words) tap to expand
STAT PlusBreaking News Supreme Court rejects challenge to Medicare drug price negotiation Drugmakers have largely failed in suits against the program Manage alerts for this article Email this article Share this article Brendan SMIALOWSKI/AFP via Getty Images By John WilkersonMay 18, 2026 John Wilkerson, a Washington correspondent, is the author of D.C. Diagnosis, a twice-weekly newsletter about the politics and policy of health and medicine. John Wilkerson[email protected]John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
